Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

A Study With RO4917523 in Patients With Fragile X Syndrome

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01015430
First received: November 17, 2009
Last updated: September 1, 2016
Last verified: September 2016
History of Changes

November 17, 2009
September 1, 2016
November 2009
January 2011   (final data collection date for primary outcome measure)
Safety, Tolerability and Pharmacokinetics: AEs, laboratory parameters [ Time Frame: AEs throughout study; laboratory assessments: days 1, 8, 15, 29, 43 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01015430 on ClinicalTrials.gov Archive Site
Efficacy: Behavior and cognition assessments [ Time Frame: Every 2 weeks throughout study ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study With RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Safety and Tolerability, and Exploratory Efficacy and Pharmacodynamic Effects Study of RO4917523 in Adult Patients With Fragile X Syndrome.
This randomized, double-blind multiple ascending dose study will evaluate the safety and tolerability, pharmacokinetics and efficacy of RO4917523 in patients with Fragile X Syndrome. The patients will be randomized to receive either active drug or placebo. The anticipated time on study treatment is 6 weeks. The target sample size is <100 patients.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Fragile X Syndrome
  • Drug: Placebo (for RO4917523 ascending doses)
    Placebo daily po
  • Drug: Placebo (for RO4917523 fixed dose)
    Placebo daily po
  • Drug: RO4917523
    RO4917523 ascending doses daily po
  • Drug: RO4917523
    RO4917523 fixed dose daily po
  • Placebo Comparator: Placebo (for RO4917523 ascending doses)
    Interventions:
    • Drug: Placebo (for RO4917523 ascending doses)
    • Drug: Placebo (for RO4917523 fixed dose)
  • Placebo Comparator: Placebo (for RO4917523 fixed dose)
    Interventions:
    • Drug: Placebo (for RO4917523 ascending doses)
    • Drug: Placebo (for RO4917523 fixed dose)
  • Experimental: RO4917523 ascending doses
    Intervention: Drug: RO4917523
  • Experimental: RO4917523 fixed dose
    Intervention: Drug: RO4917523
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
January 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients, 18 to 50 years of age
  • Fragile X Syndrome
  • IQ less than 75
  • Reliable caregiver

Exclusion Criteria:

  • Current psychosis or presumption of psychosis
  • History of suicidal behavior or considered a high suicidal risk
  • Severe self-injurious behavior
  • Any unstable medical condition other than Fragile X Syndrome (e.g. hypertension, diabetes)
  • Current seizure disorder
Both
18 Years to 50 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01015430
NP22578
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP